Professor Bill Newman, PALOH study lead and Consultant in Genomic Medicine at MFT highlights the benefits of the Genedrive® MT-RNR1 ID Kit, one of the 1st products to be assessed by #NICE in their new EVA programme.
📢Full report next week
#GDR#NHS#POCT#pharmacogenetics
Roll out of Genedrive® MT-RNR1 ID Kit across Greater Manchester hospitals. @HealthInnovMcr to support wider adoption of the rapid point of care test in neonatal units across the region #GDR#NHS https://t.co/QzfSkvNeKK
@genedriveplc (AIM #GDR) UK’s National Institute for Health and Care Excellence (NICE) has preliminarily recommended that the Genedrive® MT-RNR1 ID Kit can be used by the NHS
https://t.co/Qq7NG7Ovdi
"Our experience of using this test has been very positive. Its straightforward, non-invasive and will have a huge impact on our patients' lives." National recognition for the Manchester-led product development 👏 ⬇️
#GDR#neonatal#pharmacogenetics https://t.co/7qsRFraOPG
We are pleased to announce Connect Medizintechnik GmbH as our exclusive distribution partner in Austria for the Genedrive® MT-RNR1 product range. We look forward to working together to bring the benefits of bedside MT-RNR1 testing to Austria #GDR#hearingloss#neonatalcare
Genedrive are pleased to announce Proyectos Hospitalarios Internacional, S.A. (PRHOINSA) @prhoinsa as our commercial partner in Spain for the Genedrive MT-RNR1 product range. We look forward to working together to bring the benefits of bedside MT-RNR1 testing to Spain #GDR
The PALOH study developed and implemented a rapid genetic test to avoid hearing loss in unwell babies.
This was a huge collaborative effort between @MFT_SaintMarys, @genedriveplc, & @EGS_UoM.
🏆 Last night our team were awarded the @NewStatesman Healthcare Impact Award.
1/4
The PALOH study developed and implemented a rapid genetic test to avoid hearing loss in unwell babies.
This was a huge collaborative effort between @MFT_SaintMarys, @genedriveplc, & @EGS_UoM.
🏆 Last night our team were awarded the @NewStatesman Healthcare Impact Award.
1/4
NICE initiated the new fast track process to drive #innovation into the hands of health and care professionals to enable best practice by providing a quicker assessment of products. The Genedrive MT-RNR1 assay is the only #molecular test being evaluated #GDR#POCT